BioTrace Medical is a technology company.
BioTrace Medical has raised $3.0M across 1 funding round.
BioTrace Medical has raised $3.0M in total across 1 funding round.
BioTrace Medical has raised $3.0M in total across 1 funding round.
BioTrace Medical's investors include Azimuth Ventures, Baird Capital, Okapi Venture Capital.
BioTrace Medical is a medical technology company that developed the Tempo Temporary Pacing Lead, an active fixation device for secure, stable temporary cardiac pacing during procedures like TAVR, TMVR, and cardiac surgery.[3][4] It serves cardiologists, surgeons, anesthesiologists, and intensivists by addressing complications from conventional passive fixation leads, such as cardiac perforation (0.6-4.0% risk), dislodgment (10-37%), and delayed patient ambulation.[4] The lead solves these issues through retractable stabilizer loops and a soft tip, enabling safer pacing, rapid deployment, and earlier mobility, with over 12,000 U.S. placements showing a 0.05% perforation rate.[4] Acquired by Merit Medical, it has FDA clearance (2016) and CE Mark (2019), marking strong growth momentum from limited launch in 2017 to expanded adoption.[4][5]
BioTrace Medical emerged from Stanford Biodesign, where the idea stemmed from clinical insights into temporary pacing lead failures used by diverse physicians.[3] Founders recognized the need for a device deployable by cardiologists, surgeons, anesthesiologists, emergency doctors, and intensivists, leading to the Tempo Lead's "snap to deploy" design.[3] Key milestones include FDA 510(k) clearance in October 2016, first commercial use in December 2016, and a limited U.S. launch in early 2017, with positive feedback as "an exciting advance" and potential "new standard of care."[3][5] The company, based in San Carlos, CA, achieved CE Mark in 2019 and was later acquired by Merit Medical.[4][5]
(Note: Rare adverse events reported, e.g., one MAUDE case for temporary pacemaker wire.[7])
BioTrace Medical rides the wave of transcatheter interventions like TAVR and TMVR, where temporary pacing is routine but complication-prone with legacy leads.[3][4][5] Timing aligns with rising minimally invasive cardiac procedures, driven by aging populations and TAVR volume growth; market forces favor devices enabling faster turnover and mobility to cut hospital stays/costs.[4] It influences the ecosystem by setting a safer standard, expanding beyond TAVR (e.g., cardiac surgery), and integrating via acquisition into Merit Medical's portfolio, accelerating adoption in high-volume cath labs.[3][4][5]
Post-acquisition by Merit Medical, BioTrace Medical's Tempo Lead is positioned for wider global rollout, building on U.S./EU approvals and low complication data.[4][5] Trends like expanding TAVR indications, structural heart innovations, and value-based care will amplify demand for reliable, cost-reducing pacing tech. Its influence may evolve toward dominating active fixation temporary leads, potentially inspiring next-gen iterations for broader electrophysiology applications—redefining procedural safety from the outset.[3][4]
BioTrace Medical has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in February 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2014 | $3.0M Series A | Azimuth Ventures, Baird Capital, Okapi Venture Capital |